U.S. Markets open in 5 hrs 24 mins

Novelion Therapeutics Inc (NVLN) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Novelion Therapeutics Inc (NVLN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Novelion Therapeutics Inc is a biopharmaceutical company. It is engaged in developing patient care facility and providing services for people suffering from rare diseases like lipodystrophy, leber congenital amaurosis, and retinitis pigmentosa. Novelion Therapeutics Inc has a market cap of $23.850 million; its shares were traded at around $1.25 with and P/S ratio of 0.20. Novelion Therapeutics Inc had annual average EBITDA growth of 2.50% over the past five years.


For the last quarter Novelion Therapeutics Inc reported a revenue of $40.7 million, compared with the revenue of $38.91 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $130.4 million, a decrease of 5.8% from the previous year. For the last five years Novelion Therapeutics Inc had an average revenue decline of 0% a year. The Novelion Therapeutics Inc had an operating margin of -36.74%, compared with the operating margin of -60.87% a year before. The 10-year historical median operating margin of Novelion Therapeutics Inc is -61.81%. The profitability rank of the company is 3 (out of 10).

At the end of the fiscal year, Novelion Therapeutics Inc has the cash and cash equivalents of $45.2 million, compared with $55.4 million in the previous year. The company had no long term debt, compared with $258.5 million in the previous year. Novelion Therapeutics Inc has a financial strength rank of 2 (out of 10).

At the current stock price of $1.25, Novelion Therapeutics Inc is traded at 97% discount to its historical median P/S valuation band of $41.62. The P/S ratio of the stock is 0.20, while the historical median P/S ratio is 6.07. The stock lost 72.35% during the past 12 months.

For the complete 20-year historical financial data of NVLN, click here.

This article first appeared on GuruFocus.